Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Demcizumab Plus Pembrolizumab in Solid Tumors
NCT02722954Phase 1Completed
- Sponsor
- OncoMed Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- May 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of demcizumab in solid tumor, sponsored by OncoMed Pharmaceuticals. Primary endpoint: Dose Limiting Toxicities. Started Jan 2016; status: completed.
02
Drugs
demcizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02722954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02722954.